Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd.

SHSE:600613 Voorraadrapport

Marktkapitalisatie: CN¥3.9b

Shanghai Shenqi Pharmaceutical Investment Management Beheer

Beheer criteriumcontroles 2/4

We currently do not have sufficient information about the CEO.

Belangrijke informatie

Feng Bin

Algemeen directeur

CN¥480.3k

Totale compensatie

Percentage CEO-salarisn/a
Dienstverband CEO13.4yrs
Eigendom CEOn/a
Management gemiddelde ambtstermijngeen gegevens
Gemiddelde ambtstermijn bestuurgeen gegevens

Recente managementupdates

Recent updates

Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd.'s (SHSE:600613) 26% Share Price Surge Not Quite Adding Up

Oct 21
Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd.'s (SHSE:600613) 26% Share Price Surge Not Quite Adding Up

Why Shanghai Shenqi Pharmaceutical Investment Management's (SHSE:600613) Earnings Are Better Than They Seem

May 06
Why Shanghai Shenqi Pharmaceutical Investment Management's (SHSE:600613) Earnings Are Better Than They Seem

Investor Optimism Abounds Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. (SHSE:600613) But Growth Is Lacking

Apr 17
Investor Optimism Abounds Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. (SHSE:600613) But Growth Is Lacking

CEO

Feng Bin (52 yo)

13.4yrs

Tenure

CN¥480,300

Compensatie

Mr. Feng Bin is a Director of Shanghai Shenqi Pharmaceutical Investment Management Co.,Ltd. (formerly known as Shanghai Wingsung Investment Management Co., Ltd.) and serves as its General Manager since Jun...